1 5
A P P L I C A T I O N N O T E
References
1. Baroja-Mazo A, Barbera-Cremades M, Pelegrin P. (2013). The participation of plasma membrane hemichannels to pu-
rinergic signaling. Biochim Biophys Acta, 1828:79-93.
2. Antonio LS, Stewart AP, Varanda WA, Edwardson JM. (2014). Identification of P2X2/P2X4/P2X6 heterotrimeric receptors
using atomic force microscopy (AFM) imaging. FEBS Lett 588:2125-8.
3. Kaczmarek-Hajek K, Lorinczi E, Hausmann R, Nicke A. (2012). Molecular and functional properties of P2X receptorsere-
cent progress and persisting challenges. Purinergic Signal, 8:375-417.
4. Burnstock G, Kennedy C. (2011). P2X receptors in health and disease. Adv Pharmacol, 61:333-72.
5. Pankratov, Y. V., Lalo, U. V. & Krishtal, O. A. (2002). Role for P2X receptors in long-term potentiation. J. Neurosci.,
2002;22:8363–-8369.
6. Tsuda, M. et al. (2003). P2X 4 receptors induced in spinal microglia gate tactile allodynia a¤er nerve injury. Nature, 424,
778–-783.
7. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ,
Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K,
Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-
130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. PMID: 31767182; PMCID: PMC6812410.
8. Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin
Diabetes Healthc. 2023 Dec 8;4:1293926. doi: 10.3389/fcdhc.2023.1293926. PMID: 38143794; PMCID: PMC10739421.
9. Chilton, R.J., Wyatt, J., Nandish, S., Oliveros, R.A., & Lujan, M. (2011). Cardiovascular comorbidities of type 2 diabetes
mellitus: defining the potential of glucagonlike peptide-1-based therapies. The American journal of medicine, 124 1
Suppl, S35-53 .
10. Irwin, N., Flatt, P.R., Patterson, S., & Green, B.D. (2010). Insulin-releasing and metabolic effects of small molecule GLP-
1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. European journal of pharmacology,
628 1-3, 268-73 .
